Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release

BACKGROUND: Bispecific T-cell engagers are an established therapeutic strategy for the treatment of hematologic malignancies but face several challenges when it comes to their application for the treatment of solid tumors, including on-target off-tumor adverse events. Employing an avidity-mediated s...

Descripción completa

Detalles Bibliográficos
Autores principales: Aschmoneit, Nadine, Kühl, Lennart, Seifert, Oliver, Kontermann, Roland E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593740/
https://www.ncbi.nlm.nih.gov/pubmed/34782429
http://dx.doi.org/10.1136/jitc-2021-003616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593740/
https://www.ncbi.nlm.nih.gov/pubmed/34782429
http://dx.doi.org/10.1136/jitc-2021-003616

Ejemplares similares